고전릴게임 60.rpa216.top 바로가기 상품권릴게임, pc야마토게임

바다이야기pc게임 68.rpa216.top 알라딘게임

바다이야기 고래 출현 40.rpa216.top 최신야마토게임

온라인황금성 14.rpa216.top 온라인오션파라다이스

최신릴게임 34.rpa216.top 바다이야기릴게임

야마토2다운로드 16.rpa216.top 릴황 금성

릴게임알라딘주소 92.rpa216.top 바다이야기 환전 가능

우주전함 야마토게임 71.rpa216.top 릴게임설치

손오공릴게임예시 6.rpa216.top 야마토2동영상

뽀빠이 릴게임 25.rpa216.top 오션파라다이스사이트

릴게임 온라인 씨엔조이 94.rpa216.top 게임몰

바로가기 go !! 바로가기 go !!

야마토게임2 바다이야기 2화 릴게임연타 무료충전 바다이야기 황금성릴 바다슬롯먹튀 릴신천지 바다이야기 모바일게임 동영상황금성 릴게임 백경 릴게임 꽁머니 바다이야기 pc 버전 슬롯무료게임 온라인백경게임 릴게임추천 일본야마토 메이저릴게임사이트 바다이야기온라인 온라인황금성 모바일야마토5게임 바다이야기게임2018 황금성게임다운 바다이야기 황금고래 오션파라 다이스게임 하는법 오리 지날야마토연타예시 무료게임 양귀비 다빈치무료릴게임 해적게임 프라그마틱 홈페이지 손오공게임하기 손오공게임온라인 바다이야기환전 게임황금성 야마토 릴게임 황금성게임공략방법 릴게임바다이야기 오션파라다이스 예시 황금성게임다운로드후기 강원랜드이기는법 황금성후기 릴게임보물섬 pc릴게임 파칭코게임다운로드 릴게임 다빈치 오션파라다이스시즌7 용의눈게임 백경게임 다운로드 바다이야기 확률 야마토 무료 게임 손오공게임다운 신천지게임하는방법 다모아릴게임 바다이야기 릴게임 온라인릴게임사이트 야마토 동영상 바다이야기 무료게임 성인놀이터 예시 황금성게임장주소 체리마스터 릴게임 황금성게임종류 바다이야기슬롯 바다이야기시즌5 온라인황금성주소 바다이야기게임다운 양귀비예시 실시간릴게임사이트 빠찡코 하는 방법 강원랜드 슬롯머신 규칙 메이저릴게임사이트 황금성릴 jQuery 슬롯 머신 슬롯머신 원리 바다게임 바다이야기 슬롯 안전 슬롯사이트 오션바다이야기게임 바다이야기환전 바다이야기확률 바다이야기 프로그램 릴게임백경 바다 이야기 다운 프라그마틱 슬롯 팁 릴게임다운 백경 인터넷야마토릴게임 무료슬롯 릴게임다운로드 바다이야기5 오리 지날야마토 릴게임 다빈치 바다이야기게임하기 황금성후기 황금포카성 바다이야기부활 릴게임바다이야기 바다이야기 5만 온라인배경 손오공 게임 다운 알라딘게임랜드 슬롯 검증사이트 황금성게임다운로드후기 슬롯머신 영어로 슬롯 추천 디시 알라딘다운로드 야마토게임다운로드 온라인오션파라다이스 온라인신천지 슬롯릴게임 바다이야기게임하는방법 오리지날야마토 바다이야기 모바일게임 바다시즌7게임 오션파라 다이스게임 하는법 바다이야기 무료 알라딘먹튀 손오공게임하기 유희왕황금성 릴게임 체리마스터 파친코게임 바다이야기하는곳 야마토창공 오션파라다이스 예시 슬롯 게시판 This article was released as Pharm Edaily Premium Content on August 1, 2025, at 8:30 AM.


[Lim Jeong-yeo, Edaily Reporter] On July 31, shares of HK inno.N, Cellbion, and Rokit Healthcare gained ground in the Korean pharmaceutical, biotech, and medical device sectors. HK inno.N met 500 billion won revenue threshold for the first time for H1 earnings. Cellbion gained 개인회생대출가능한곳 traction in anticipation of its prostate cancer treatment’s Phase 2 clinical data readout, estimated to take place this month. Rokit Healthcare drew interest after signaling plans to acquire a company 파산면책제도 using funds raised through recently issued convertible bonds.



HK inno.N chart(Cred=KG Zeroin MP Doctor)



HK 차상위계층 조건 inno.N: Earnings, Comirnaty Contract, and U.S. Phase 3 Trial Drive Momentum

HK inno.N closed at 45,000KRW on Thursday, up 6.76% (2,850 KRW) from the previous session. The rally fo 전포 한라비발디 llowed the release of second-quarter results showing 263 billion KRW in revenue, a 20% increase year-on-year. This brought first-half cumulative revenue to 510 billion KRW, an 18% increase over the sa 한국장학재단 로그인 me period last year, marking the company’s first time surpassing 500 billion KRW threshold in H1 sales.
Investor optimism was further bolstered by progress on K-CAB, HK inno.N’s gastroesophageal reflux disease treatment, which is nearing the completion of its U.S. Phase 3 maintenance trial. The company also secured a domestic supply contract for COVID-19 vaccine Comirnaty with Pfizer last year and on July 29 was selected as the National Immunization Program(NIP) distributor. The contract covers 3.281 million doses with a total value of 213.9 billion KRW. Notably, COVID-19 vaccines were included in Korea’s NIP for the first time this year.
An HK inno.N representative said, “Implementation of the Comirnaty NIP contract is imminent, and the U.S. Phase 3 maintenance trial for K-CAB is also expected to wrap up in Q3.”



Cellbion chart(Cred=KG Zeroin MP Doctor)



Cellbion Set to Reveal Phase 2 Data for Prostate Cancer Drug

Cellbion closed at 29,050 KRW on Thursday, up 4.68% (1,300 KRW) from the day before. Shares gained on anticipation that Phase 2 trial results for 177Lu-DGUL, a radiopharmaceutical for metastatic castration-resistant prostate cancer(mCRPC), will be released in August.
Having listed on KOSDAQ last October, Cellbion is among the most advanced R&D players in Korea’s radiopharmaceutical space. 177Lu-DGUL targets the third-line treatment market for patients with mCRPC who have failed all existing therapies.
Cellbion plans to use the Phase 2 data to pursue conditional approval within the country. The company aims to launch the product in the first half of next year and generate approximately 20 billion KRW in revenue in the first year of launch. These projections were previously shared via Edaily’s premium content platform.



Rokit Healthcare chart(Cred=KG Zeroin MP Doctor)



Rockit Healthcare Gains on Foreign Investment in CB

Rockit Healthcare ended the day up 2.32% (350 KRW), closing at 15,460 KRW. The uptick is believed to be influenced by a PharmEdaily Premium article published that day.
Just three months after raising 17 billion KRW through a KOSDAQ IPO in May, Rockit issued 30 billion KRW worth of convertible bonds. The funds are earmarked for 22 billion KRW in operating capital and 8 billion KRW for strategic acqusition.
In an interview with Edaily, Lee Yong-gyu, CFO of Rokit Healthcare, stated that the funds would support clinical work beyond diabetic foot ulcers, including cartilage and kidney regeneration. He added, “We’re planning to acquire a company worth around 10 billion KRW to create strategic synergy.”
Among CB investors, Oasis Investment, a foreign fund, stood out by contributing 8 billion KRW (roughly 30% of the issuance). NH Investment & Securities and Korea Investment & Securities also participated, investing 7.2 billion KRW and 2 billion KRW respectively.
임정요 (kaylalim@edaily.co.kr)

추천0 비추천0